Here are the 10-K annual reports from Antiaging Qntum LGN A (AAQL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AAQL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AAQL filings page.
Antiaging Quantum Living Inc., a New York holding company, reports results for the year ended March 31, 2026 while pivoting from online platform technical services to proprietary health and beauty products and offline therapy services under its Dao Ling Doctor brand in China, alongside a small U.S. online advertising business.
Revenue reached $1,034,385, up from $817,898. Of this, $711,607 came from legacy platform services being phased out, while new therapy services contributed $141,828 and proprietary products $180,950. Gross profit rose to $702,123 with a 67.9% gross margin versus 52.4% a year earlier, but operating expenses increased to $1,537,524, leading to a net loss of $837,646 compared with a $720,409 loss in 2025.
At March 31, 2026, cash and cash equivalents were $503,486, with an accumulated deficit of $2,247,358 and a working capital deficit of $459,038. Management and the auditor state these conditions raise substantial doubt about continuing as a going concern. Operations are being funded mainly by shareholder loans and other borrowings. In November 2025, $1,284,102 of promissory notes converted into 4,280,340 Class A shares at $0.30 per share, lifting outstanding Class A shares to 34,275,340, and authorized common stock has been increased to 6,000,000,000 shares across five classes.